Authors


Gerald Jerome, PhD

Latest:

Obese Breast Cancer Patients and Survivors: Management Considerations

This article will present feasible weight loss interventions, and will discuss practical implications of ongoing chemotherapy and endocrine therapy with regard to weight gain, and the impact of obesity on therapy-related conditions during breast cancer survivorship.


Cletus Arciero, MD, FACS

Latest:

Multidisciplinary Approaches to Chest Wall Recurrences of Breast Cancer

A chest wall recurrence of breast cancer following mastectomy is a complex clinical problem that can push centers to the limits of their resources.


Peter Thompson, MD

Latest:

Multidisciplinary Approaches to Chest Wall Recurrences of Breast Cancer

A chest wall recurrence of breast cancer following mastectomy is a complex clinical problem that can push centers to the limits of their resources.


Mylin A. Torres, MD

Latest:

Multidisciplinary Approaches to Chest Wall Recurrences of Breast Cancer

A chest wall recurrence of breast cancer following mastectomy is a complex clinical problem that can push centers to the limits of their resources.


Andrew S. Poklepovic, MD

Latest:

Prognostic Value of Low Tumor Burden in Patients With Melanoma

In this article, we review the role of baseline tumor size in response and survival on traditional and contemporary therapies for the treatment of locoregional and distant melanoma recurrences.


Sinziana Dumitra, MD, MSc, FRCSC

Latest:

The Diagnosis and Management of Retroperitoneal Sarcoma

Retroperitoneal sarcoma is a rare tumor whose diagnosis and management can be challenging and for which management requires a multidisciplinary team.


Eric Ko, MD, PhD

Latest:

Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer

ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.


Marcus E. Randall, MD

Latest:

POINT: Should Radiation Therapy Be Routinely Used in the Adjuvant Treatment of Stage III Endometrial Cancer?

Adjuvant radiation therapy provides a local control benefit in stage III endometrial carcinoma patients, as strongly suggested in retrospective and prospective series.


Mark E. Bernard, MD

Latest:

POINT: Should Radiation Therapy Be Routinely Used in the Adjuvant Treatment of Stage III Endometrial Cancer?

Adjuvant radiation therapy provides a local control benefit in stage III endometrial carcinoma patients, as strongly suggested in retrospective and prospective series.


John P. Diaz, MD, FACOG

Latest:

COUNTERPOINT: Should Radiation Therapy Be Routinely Used in the Adjuvant Treatment of Stage III Endometrial Cancer?

The routine use of adjuvant radiation therapy in stage III endometrial cancer patients is not supported by the current literature and should not be employed universally in this group of patients.


Tejas Patil, MD

Latest:

CRESTONE Trial of Seribantumab in Solid Tumors With NRG1 Fusions: Real-World Implications

Looking toward the future management of solid tumors with NRG1 fusions, expert panelists consider how the availability of seribantumab therapy may impact their practice.


Naveed Saleh, MD, MS

Latest:

Alpelisib Is Changing the Clinical Landscape in Breast Cancer Treatment

The US Food and Drug Administration recently approved alpelisib plus fulvestrant for the treatment of metastatic or otherwise advanced breast cancer.


Ranjit Manchanda, MD, PhD

Latest:

Population Testing to Prevent Gynecologic Cancers

Dr. Ranjit Manchanda speaks with Cancer Network about using population testing to predict and prevent gynecologic cancers.


Judi M. Fouladbakhsh, PhD, RN

Latest:

Holistic Cancer Therapy and Symptom Management

Professor Judi Fouladbakhsh speaks with Cancer Network about evidence-based holistic approaches to cancer care.


Elizabeth Ercolano, DNSc, RN

Latest:

Managing Psychosocial Distress: Lessons Learned in Optimizing Screening Program Implementation

This article discusses “lessons learned” on managing psychosocial distress and the optimal strategies to promote institutions’ adoption of distress screening.


Emma Hoffman, BS, MSN

Latest:

Managing Psychosocial Distress: Lessons Learned in Optimizing Screening Program Implementation

This article discusses “lessons learned” on managing psychosocial distress and the optimal strategies to promote institutions’ adoption of distress screening.


Hui Tan, MSN

Latest:

Managing Psychosocial Distress: Lessons Learned in Optimizing Screening Program Implementation

This article discusses “lessons learned” on managing psychosocial distress and the optimal strategies to promote institutions’ adoption of distress screening.


Nicholas Pasacreta, BA

Latest:

Managing Psychosocial Distress: Lessons Learned in Optimizing Screening Program Implementation

This article discusses “lessons learned” on managing psychosocial distress and the optimal strategies to promote institutions’ adoption of distress screening.


Mark Lazenby, PhD, APRN

Latest:

Managing Psychosocial Distress: Lessons Learned in Optimizing Screening Program Implementation

This article discusses “lessons learned” on managing psychosocial distress and the optimal strategies to promote institutions’ adoption of distress screening.


Annerleim Walton-Diaz, MD

Latest:

When to Order an MRI in the Initial Evaluation and Management of Prostate Cancer

This article summarizes the current role of multiparametric MRI in the diagnosis, risk assessment, and treatment of prostate cancer.


Soroush Rais-Bahrami, MD

Latest:

When to Order an MRI in the Initial Evaluation and Management of Prostate Cancer

This article summarizes the current role of multiparametric MRI in the diagnosis, risk assessment, and treatment of prostate cancer.


Jennifer Weiss, MD

Latest:

Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer

An otherwise healthy 58-year-old woman with a history of breast cancer presents to the clinic with newly diagnosed metastatic disease; eventual abdominal CT showed a mass in the transverse colon with ascites and peritoneal nodularity. What is the best initial systemic treatment for her?


Anosheh Afghahi, MD

Latest:

Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer

An otherwise healthy 58-year-old woman with a history of breast cancer presents to the clinic with newly diagnosed metastatic disease; eventual abdominal CT showed a mass in the transverse colon with ascites and peritoneal nodularity. What is the best initial systemic treatment for her?


K. Simon Yeung, PharmD, LAc

Latest:

Herb-Drug Interactions in Cancer Care

In this article, we describe the mechanisms via which interactions between herbs and prescription drugs may occur, and highlight four popular herbs and a medicinal mushroom commonly used by cancer patients, along with reports of their interactions with standard drugs.


Emily Wynja, MSIV

Latest:

A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited Tissue

Due to the high rate of EGFR T790M mutations seen in NSCLC patients, the thoracic tumor board recommends genomic testing for this alteration; read our case of a 69-year-old woman with metastatic disease.


Jenna Hove, BSN

Latest:

A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited Tissue

Due to the high rate of EGFR T790M mutations seen in NSCLC patients, the thoracic tumor board recommends genomic testing for this alteration; read our case of a 69-year-old woman with metastatic disease.


Steven F. Powell, MD

Latest:

A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited Tissue

Due to the high rate of EGFR T790M mutations seen in NSCLC patients, the thoracic tumor board recommends genomic testing for this alteration; read our case of a 69-year-old woman with metastatic disease.


Anureet C. Copeland, MD

Latest:

Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going

This article discusses the advances in HER2-targeted therapy, in both the metastatic and adjuvant settings, with a focus on those with early-stage breast cancer.


Cara Wilt, CRNP

Latest:

Integrating Immunotherapy Into Colorectal Cancer Care

Until recent studies were reported, immunotherapy was thought to be ineffective for colorectal cancer; this article provides guidance on how to incorporate immunotherapy into this setting.


Ian Flinn, MD, PhD

Latest:

Recognizing the Side Effects of Newly Approved CLL Therapies

Dr. Ian Flinn spoke with Cancer Network about incorporating the newest approved therapies for the management of CLL.